Sato H, et al. - Authors assessed the effect of pre-treatment prognostic factors and early changes in serum biomarkers on prostate-specific antigen (PSA) progression-free and overall survival rates in metastatic hormone-sensitive prostate cancer (mHSPC). As per the data, a probability of an increased level of PSA at baseline or an EOD score of ≥3 to be a good predictor of PSA progression was seen. At 12 weeks, a high level of ALP could be a risk predictor of death. Experts noted an association of a larger decline in PSA at 12 weeks from the baseline with both PSA progression-free and overall survival time. Poor outcomes could be predicted in patients with mHSPC who were initially treated with ADT with early changes in serum biomarkers.